lundi 25 novembre 2013

Depression Defined: Symptoms, Epidemiology, Etiology and Treatment

Depression is a term that has been used to describe a variety of ailments ranging from minor to incapacitating. Clinically significant depression, termed major depression, is a serious condition characterized not only by depressed mood, but a cluster of somatic, cognitive, and motivational symptoms. Major depression can be differentiated from a normal and transient sad mood by several factors:

intensity, as major depression causes impairment in social or occupational functioning and persists across time and situationsrelationship to antecedent events, as major depression either occurs without any identifiable antecedent event or is clearly in excess of what would be considered an expected reactionquality, with the quality of the emotion being different from that experienced in a normal sad moodassociated features, as the mood co-occurs with a group of other cognitive and somatic symptomshistory, with major depression typically appearing after a history of other such episodes (Whybrow et al 1984).

Individuals who are suffering from major depression often report feeling overwhelmed, helpless, despairing, suffocated, or numb. Major depression can range from mild sadness to complete hopelessness and is often accompanied by frequent crying spells. Those with more severe depression may feel like crying but be unable to do so. Severely depressed individuals often believe that no one can help them.

Depression is defined according to specific criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) (American Psychiatric Association (APA) 1994).

The DSM-N details the diagnostic criteria for nearly 300 mental dis-orders, and nearly 100 other psychological conditions that might be the focus of professional attention. While many individuals experiencing a debilitating depression will meet criteria for one of the disorders within the DSM-IV, some will nonetheless elude classification using this system. The following sections detail the different disorders within the DSM-IV that may involve depressive symptoms, following which an overview of etiology and treatment — for the non-specialist — is provided.

In order to be diagnosed with a major depressive episode according to the DSM-IV, an individual must have at least five out of nine possible symptoms, which must be present during the same 2-week period and represent a change from a previous level of functioning. One of the symptoms must be either depressed mood for most of the day on nearly every day, or loss of interest or pleasure (anhedonia) in all or almost all activities for most of the day on nearly every day. Additional symptoms that may accompany the depressed mood or anhedonia are:

significant weight loss (when not dieting) or significant weight gain (i.e. more than 5% of body weight in 1 month), or a decreased or increased appetite nearly every dayinsomnia or hypersomnia nearly every dayobservable psychomotor agitation or retardation nearly every dayfatigue or loss of energy nearly every day, feelings of worthlessnessor excessive or inappropriate guilt nearly every daydiminished ability to think or concentrate, or indecisiveness nearly every dayand recurrent thoughts of death (not just fear of dying) or suicide.

‘Depression is also often diagnosed according to criteria outlined in the ICD-10 Classification of Mental and Behavioral Disorders (World Health Organization 1992). ICD-10 criteria overlap substantially, but are not identical to, those of the DSM-IV. This post focuses on the criteria of the DSM-IV because the studies reviewed here have predominantly relied on these criteria for diagnosing depression.

The symptoms must be present for at least 2 weeks and cause clinically significant distress or impairment in social, occupational, or other areas of functioning. Additionally the mood disturbance should not be the direct physiological effect of a substance (e.g. street drug or medication) or general medical condition (e.g. hypothyroidism) (APA 1994). Individuals who meet criteria for a major depressive episode and have never experienced any manic or hypomanic episodes (see below) then meet criteria for major depressive disorder.

Unipolar Versus Bipolar Depression

The DSM-IV distinguishes two broad classes of mood disorder: unipolar and bipolar disorder. Unipolar disorders involve only the depressed dimension of mood and do not include periods of above-average mood such as manic or hypomanic episodes. There are two unipolar mood disorders: major depressive disorder and dysthymic disorder. Bipolar disorders include those in which the individual experiences both depressed moods and manic or hypomanic episodes. The three bipolar disorders described in DSM-IV are bipolar I disorder, bipolar II disorder, and cyclothymic disorder.

Dysthymia

Another form of depression that is less intense but more chronic than major depressive disorder is dysthymia. Distinguishing between a diagnosis of major depressive disorder and dysthymia is difficult because the two share many symptoms and the differences in onset, duration, persistence, and severity are difficult to evaluate retrospectively. In order to meet DSM-IV criteria for dysthymic disorder, an individual must experience depressed mood for most of the day, more days than not for at least 2 years. In children and adolescents, irritable mood would also suffice to meet the criteria, and must last for at least 1 year. Two or more additional symptoms must also be present: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration or difficulty making decisions, and feelings of hopelessness. At no time during the 2-year period has such a person been without the depressive symptoms for more than 2 months at a time. If the person has met criteria for major depression at any point during the 2-year period, the diagnosis would be considered as major depression instead of dysthymia. However, an individual who has met criteria for dysthymia for at least 2 years and then subsequently meets the criteria for an episode of major depression superimposed on the dysthymia (without an intervening remission) would be given both diagnoses. This condition is referred to as double depression. It is particularly difficult to differentiate double depression from simple major depressive disorder or chronic major depressive disorder for the reasons mentioned above, combined with the fact that all three meet criteria for a major depressive episode and they differ only in onset, duration, and persistence. A history of mania (at least one manic episode) would rule out a diagnosis of both major depression and dysthymia (APA 1994).

Mania and Bipolar Disorder

Mania is the mood state that is the apparent opposite of depression. Mania involves a euphoric or elated mood that lasts for at least 1 week. A manic episode is more than just a normal good mood; rather, the person feels like he or she is on top of the world and there is nothing he/she can’t do. The euphoric mood is accompanied by at least three other symptoms, including: inflated self-esteem or grandiose beliefs (e.g. that the patient is President or some other famous person of importance), a decreased need for sleep (i.e. feels rested after only 3 h of sleep), a pressure to keep talking, the subjective experience that one’s thoughts are racing, distractibility, increase in activity (either socially, at work or school, or sexually), and excessive involvement in pleasurable activities that have a high potential for painful consequences (e.g. unrestrained buying sprees, sexual promiscuity, etc.). In addition, the mood disturbance must cause impairment in functioning (either social or occupational), or require hospitalization to prevent harm to self or others, or involve psychotic features (e.g. hallucinations). Furthermore, a manic episode is not diagnosed if the symptoms are caused by street drugs, medication or other treatment, or a general medical condition (APA 1994).

A person who has experienced at least one manic episode would meet the criteria for bipolar I disorder. Most individuals who meet criteria for bipolar I have also experienced episodes of major depression in addition to manic episodes; however, this is not necessary for the diagnosis.

Some individuals experience a mood disturbance called hypomania that is similar to a manic episode, but not as severe. The criteria for hypomania are the same as the criteria for a manic episode (described above); however, hypomania must only be present for at least 4 days (versus 1 week for a manic episode), and the episode must not cause impairment in functioning or require hospitalization. Individuals who have experienced at least one major depressive episode, at least one hypomanic episode, and no fully developed manic episodes would be give a diagnosis of bipolar II disorder (APA 1994).

Cyclothymia

Cyclothymia is a more chronic but less intense form of bipolar disorder. To meet criteria for cyclothymia, an individual must experience numerous periods of hypomania and depressed mood over a period of at least 2 years. In fact, the person cannot show the absence of both hypo-manic and depressive symptoms for a period of more than 2 months. Moreover, in cyclothymia there are no major depressive episodes or manic episodes during the first 2 years of the disorder (APA 1994).

Although it is possible that acupuncture may prove effective in treat-ing many varieties of depression, our previous clinical trial (Allen et al 1998) examined only major depressive disorder, and this manual is designed for use with major depressive disorder. With modifications, it is possible that the framework detailed in the subsequent posts could be adapted for use with other depressive disorders.

Specifiers of Major Depression

To capture more adequately the range of mood disorders, the DSM-IV additionally provides for the inclusion of specifiers, which can be used to describe the current or most recent major depressive episode included. These specifiers include chronic, with melancholic features, severe with psychotic features, postpartum onset, and atypical. In addition, the course of the disorder can be specified as `with seasonal pattern’, which is considered a subtype of major depression also known as seasonal affective disorder. The bipolar disorders can be specified as rapid cycling.

The costs of major depression are substantial, and exceed those of other chronic diseases such as diabetes and hypertension in terms of personal distress, lost productivity, interpersonal problems, and suicide. A recent study estimated that these annual costs of depression in the United States exceeded $40 billion (Hirschfeld & Schatzberg 1994), and similar findings have emerged from a worldwide study (Murry & Lopez 1996) that ranked unipolar major depression as the number one cause of disability in the world. Over 80% of individuals who committed suicide were clinically depressed in the months before their death, and the lifetime risk for suicide among those with clinical depression is 15% (Hirschfeld & Schatzberg 1994). Furthermore, depressed individuals appear to be at increased risk of death from all causes. A 16-year prospective study found that mortality rates for depressed individuals are 1.5-2 times those of nondepressed individuals (Murphy et al 1987). Clearly, depression is a prevalent disorder with costly and potentially lethal consequences (Gotlib & Beach 1995).

Comorbidity of Major Depression with other Mental Disorders

Comorbidity is the presence of two or more disorders simultaneously. Comorbid conditions are generally more chronic, do not respond as well to treatment, and have a poorer prognosis than single disorders. It is important to be aware of the issue of comorbidity because a large proportion of individuals in the general population have more than one mental disorder concurrently (Kessler et al 1994). Outcome studies usually examine efficacy for individuals with only one disorder. Therefore, the average clinician deals with much more complicated cases than outcome research addresses (Greenberg & Fisher 1997). In fact, the National Comorbidity Survey found that it was more common to have two or more mental disorders than to have only one (Kessler et al 1994).

Dysthymia is present before the onset of a major depressive dis-order in approximately 10% of epidemiological samples. Other forms of mental illness may be present concurrent with major depressive disorder, such as: alcohol abuse or dependence disorder, personality disorders (e.g. borderline personality disorder), panic disorder, and other anxiety disorders (APA 1994). The literature demonstrates that 33-59% of people who are dependent on alcohol eventually meet criteria for depression at some point during the dis-order (Merikangas & Gelernter 1990). The comorbidity of personality disorders in clinically depressed individuals is 50% or greater (Zimmerman et al 1991). The comorbidity of anxiety disorders with depression is particularly high, in the range of 30% (Hiller et al 1989) to 57% (Mannuzza et al 1989). Research demonstrates that between 15 and 30% of individuals with acute major depression also suffer from panic disorder concurrently (Brown & Barlow 1992). The diagnostic criteria of anxiety and depression overlap, which increases the probability of meeting criteria for both disorders simultaneously. This overlap makes it difficult to know whether there exist two separate classes of conditions — anxiety and depression — or whether there may exist a single underlying predisposition that manifests with both depression and anxiety symptoms (see Frances et al 1992). In addition, the overlap increases lifetime comorbidity (i.e. meeting criteria for both depression and an anxiety disorder) between the disorders (Klerman 1990). The comorbidity of anxiety disorders with depression poses a taxonomic enigma (see Frances et al 1992) for diagnosticians and those interested in etiology.

In addition, 20-25% of individuals with general medical conditions such as diabetes, myocardial infarction, carcinoma, and stroke meet criteria for major depressive disorder at some point during the course of their illness (APA 1994). Depression may occur in the context of medical illness for three reasons: (1) the depression appears to represent a reaction to the burden and limitations associated with having a disease, (2) the depression is unrelated to the disease, but is a recurrence of a long-standing history of depression, or is in response to some other event in the person’s life, or (3) the depression occurs as a direct physiological consequence of the medical condition (e.g. mul-tiple sclerosis, stroke, hypothyroidism). In this latter case the diagnosis is technically not major depressive disorder, but rather mood disorder due to a general medical condition. A mood disorder can also be directly etiologically related to the use of a medication or a drug of abuse. In that case a diagnosis of substance-induced mood disorder (e.g. cocaine-induced mood disorder) is made instead of major depressive disorder. However, this diagnosis is reserved for depression that is a direct physiological consequence of the drug abuse or medication use; for example, the depressed mood is only present following withdrawal from cocaine (APA 1994).

This latter determination is often difficult to make because of the high rates of comorbid substance abuse or dependence disorders and mood disorders. In some cases individuals may begin using substances in response to depression, in an unfortunate attempt to cope with their pain. In such a case, major depression would be comorbid with sub-stance abuse, and both diagnoses would be given. In other cases, it could be that a pre-existing substance abuse disorder appeared to cause the depression through direct physiological means (e.g. cocaine withdrawal), in which case the diagnosis would be substance-induced mood disorder (see DSM-IV for further clarification of these diagnostic issues).

A variety of well-researched treatments exist for depression, and most have rather favorable results. These treatments include both psychotherapies and drug therapies. Unfortunately, however, the effectiveness of these traditional treatments is hampered by high rates of dropout, recovery failure, and relapse, suggesting that these traditional treatments may provide insufficient or transient symptom relief for many.

The National Institutes of Mental Health Treatment of Depression Collaborative Research Program was a clinical trial designed to investigate the efficacy of two brief psychotherapies (interpersonal psychotherapy and cognitive behavior therapy) and a drug treatment (pharmacotherapy with imipramine hydrochloride, a tricyclic antidepressant), all compared with a control group consisting of clinical management combined with pill-placebo as treatments for major depression. In this NIMH treatment study, 32% of patients who were randomized to treatment discontinued treatment prematurely. Excluding patients who dropped out for external reasons or because they had improved, 25% of all patients entering treatment terminated due to negative effects of the treatment such as dissatisfaction with treatment, desire for another treatment, intolerable side effects, and noncompliance (Elkin et al 1989). Among patients who had completed 15 weeks of pharmacotherapy or psychotherapy (not including the placebo group), 43-49% failed to recover to the point of having few symptoms, and among all patients including completers and non-completers 30-64% did not have significant symptom relief at the end of treatment (Elkin et al 1989).

Advocates of standard antidepressant medications (e.g. tricyclics such as imipramine) generally acknowledge that about one-third of patients do not improve with medication, one-third display improve-ment with placebos, and the remaining third demonstrate improve-ment that would not occur with placebo (Greenberg & Fisher 1997). In a meta-analysis (a statistical literature review that has compressed the results of large numbers of studies) of antidepressant outcome in which clinician bias was minimized, Greenberg et al (1992) found that effect sizes were approximately one-half to one-quarter as large as those found in previous studies in which clinician bias was not minimized. Clinician bias was reduced by examining the effectiveness of standard antidepressant tricyclic medications compared with newer antidepressants (serotonin reuptake inhibitors; SSRIs) as well as a placebo control. Presumably, in studies with such a design there is less motivation to establish the efficacy of the standard antidepressants, yet their effects can still be compared with those of a placebo control. With the advent of a new generation of antidepressants (SSRIs), it was hoped that they would be superior in treating depression to the older medications. A meta-analysis of all of the double-blind placebo-controlled efficacy studies of fluoxetine (Prozac) found that it was modestly effective in treating depression and resulted in response rates similar to those obtained in previous meta-analyses of tricyclic antidepressants (Greenberg et al 1994). Other meta-analyses and reviews have also found that new-generation antidepressants have equivalent outcomes to tricyclics (e.g. Anderson & Tomenson 1994, Edwards 1992, 1995, Kasper et al 1992).

It has been suggested that there may be some preference for SSRIs over tricyclics because they cause less sedation and fewer anticholinergic effects and cardiac complications than the standard tricyclics; however, they are associated with other side effects such as nausea, diarrhea, weight loss, agitation, anxiety, and insomnia (Edwards 1995; see below for details about the side effects of tricyclics, monoamine oxidase inhibitors (MAOIs), and SSRI antidepressants). Although drop-out rates from medication treatment studies are high regardless of the type of antidepressant used, the side effects of SSRIs may be slightly better tolerated by some people. These differences in tolerability are very small and may not be clinically meaningful. Furthermore, the number of patients completing each type of treatment is approximately equivalent (Greenberg & Fisher 1997).

The average effect in psychotherapy outcome research is one standard deviation, which is statistically large. An effect size of one standard deviation means that the average person receiving psychotherapy is better off than 84% of the people in the control condition who did not receive psychotherapy. In five meta-analyses of outcome with depression, psychotherapy outperformed no-treatment and wait-list controls (Lambert & Bergin 1994). Effect sizes produced by psychotherapy are equal to or greater than effects produced by various medical and educational interventions (Lambert & Bergin 1994).

For example, psychotherapy is as effective as or more effective than antidepressant medication (Dobson 1989, Robinson et al 1990, Steinbrueck et al 1983). When the allegiance of investigators and the differences between treatments are taken into account, the effectiveness of psychotherapy and pharmacotherapy is equivalent (Robinson et al 1990, Steinbrueck et al 1983). The results of the NIMH Collaborative Depression study, the largest and most well-controlled psychotherapy study conducted to date, support this notion. The NIMH study utilized investigators who were committed to each type of therapy compared and found little evidence for significant differences between therapies (Elkin et al 1989).

These findings are significant because antidepressants are often considered the treatment of choice for depression. Evans and colleagues (1992) found that psychotherapy may have an advantage over antidepressants in terms of decreased vulnerability to relapse. In addition, psychotherapy is not accompanied by the somatic side effects that occur with antidepressants. However, there is some evidence that antidepressants may start to work faster than psychotherapy and may be more effective with endogenous depressions ( Lambert & Bergin 1994 ).

Relapse, Recurrence and the Role of Maintenance Treatments

Depression tends to be a chronic and recurrent disorder. A naturalistic study of depression found that 70% of people recover from depression after 1 year and 81% after 2 years. Unfortunately, 12% of depressed individuals do not recover until 5 years after the onset of the episode and 7% of individuals suffering from depression remain chronically depressed (Hirschfeld & Schatzberg 1994).

Even once successfully treated, depression is likely to recur. Without further treatment, one-fifth of previously recovered persons once again meet criteria for major depression 6 months after the completion of treatment, and nearly one-quarter will develop new depressive symptoms. Within 18 months, over one-third of those persons who were remitted will once again meet criteria for full depression (Shea et al 1992). Ten years after an initial episode, 76% of patients will have a recurrence of depression. For those who have experienced two episodes, there is an 80-90% chance of experiencing a third episode (Hirschfeld & Schatzberg 1994). A growing consensus among those who treat depression is that, after recovery, some form of continued maintenance treatment is necessary.

Whereas research into the pharmacotherapy of depression has provided ample data concerning response to acute treatment, much less is known about the long-term efficacy of antidepressants. The available data suggest that a substantial proportion (10-34%) of patients who have responded to pharmacotherapy experience a return of depression during continued treatment (Belsher & Costello 1988, Doogan

Caillard 1992, Evans et al 1992, Frank et al 1990, Montgomery et al 1988, Prien & Kupfer 1986, Prien et al 1984, Robinson et al 1991, Thase 1990). Even greater recurrence rates are reported during long-term treatment for more severe depression. For example, Prien et al (1984) reported a 52% recurrence rate in patients on imipramine and Glen (1984) reported 68-70% recurrence rate in those on amitrip-tyline or lithium. Taken together, these data highlight the recurrent nature of mood disorders even during the course of long-term treatment and magnify the importance of developing alternative approaches for both short- and long-term treatment of depression.

Only a few studies have examined the effectiveness of psychotherapy maintenance — continued treatment designed to help keep a person from returning to a depressed state. These studies indicate that maintenance psychotherapy (alone or in combination with pharmacotherapy) helps to prevent or delay relapse or recurrence of depression. Based on a limited number of studies, cognitive therapy appears to be an effective maintenance treatment and may delay the onset of subsequent episodes of depression (Blackburn et al 1986). Although following a 6-month continuation phase relapse rates did not differ between cognitive therapy, cognitive therapy plus antidepressant drug of choice (typically amitriptyline or clomipramine), and antidepressant-alone groups, those participants receiving cognitive therapy (alone and in combination with antidepressants) had a significantly lower relapse rate than patients receiving antidepressants alone. Even without maintenance, similar results were obtained in a 2-year follow-up (Evans et al 1992). At the end of a 2-year follow-up in which no maintenance treatments were provided, patients who had received cognitive therapy (with or without medication) had significantly lower relapse rates (21% and 15%) than those who had received antidepressants only (50%) during a 3-month acute treatment phase. Another group that was continued on antidepressants for the first year of follow-up had an intermediate relapse rate (32%), which did not differ significantly from that of the other groups. Limited sample sizes (10 to 13 per group), however, make interpretation of the nonsignificant difference precarious. Collectively, these findings suggest that cognitive therapy is at least as effective as antidepressant medication in preventing relapse or recurrence.

There are also indications that interpersonal psychotherapy (IPT) provides some benefit as a maintenance treatment. An 8-month maintenance study (Klerman et al 1974) found that weekly IPT produced lower relapse rates (17%) than placebo combined with monthly 15-min IPT sessions (31%). The group receiving IPT weekly performed almost as well as the groups receiving amitriptyline and monthly IPT (12% relapse) and the amitriptyline combined with weekly IPT group (12.5% relapse). A 3-year maintenance study (Frank et al 1990) found that IPT alone, given once a month, had a recurrence rate of 60%, a rate between that of the medication groups and the placebo group. It should be noted, however, that imipramine maintenance was given in a much higher dosage than in any previous maintenance study and IPT was given in a much lower dosage (monthly) than found effective in previous studies. Nonetheless, the IPT maintenance treatments significantly lengthened the mean time of remission (survival rate) to over 1 year, compared with the placebo group with a mean duration of remission of 38 weeks.

Psychological Theories

Depression undoubtedly has many causes, and no single cause is likely to provide an adequate explanation. Different individuals may have different factors that contribute to their depression, and for any given individual multiple factors will contribute. Below we discuss some of the most widely researched factors that are thought to contribute to depression.

Learned Helplessness

The learned helplessness model posits that feelings of helplessness underlie depression. This model is based on research with both humans and animals, and has detailed how animals and humans learn that their efforts do not affect their situation and as a result they give up. Learning that behavior does not influence the situation causes motivational, cognitive, and emotional changes that resemble those in depression (Seligman 1975). Humans learn to feel helplessness not only by being in an uncontrollable situation, but also by coming to expect that their behavior will not affect important outcomes. When individuals stop expecting their responses to have an effect, they may cease trying. They have little motivation to try to escape or change situations because they have learned that nothing will change, despite their efforts. Learned helplessness also diminishes the chances that a person will later learn that responses do alter a situation. For example, dogs that were placed in a shuttle box and exposed to unavoidable inescapable shock later failed to attempt an escape when they were placed in a shuttle box in which they could escape the shock by jumping over the barrier. Learned helplessness produces affective deficits because an individual experiences negative cognitions as a result of learned helplessness (Abramson et al 1978).

The theory was revised when research demonstrated that most people do not become depressed when they experience an uncontrollable negative event. According to the reformulated theory (Abramson et al 1978), some people demonstrate a `depressogenic’ attributional style in which they explain negative events using internal, stable, and global reasons. Individuals can make either internal or external attributions about the reasons for negative events (e.g. it was my fault versus it was someone else’s fault). Those who make internal attributions are likely to suffer a loss of self-esteem because they feel that the uncontrollable situation stems from their inadequacy, whereas those who make external attributions believe their helplessness is a result of the situation and realize that the situation will change (Abramson et al 1978).

Another factor that affects an individual’s emotional reaction to an event is whether he or she generalizes the helplessness to all situations (makes a global attribution) or specifies that the helplessness occurs only in this particular situation (makes a specific attribution) (Abramson et al 1978). If individuals believe the negative event is due to a transitory factor (e.g. they failed the test because they did not feel well), they will make an unstable attribution that will result in only a short-lived depressive reaction. In contrast, a stable attribution about something that is unlikely to change will result in prolonged negative feelings about the event; for example, they failed the test because they are stupid (Abramson et al 1978). Research has demonstrated that an internal, stable, and global attributional style is a marker for vulnerability to depression (Seligman & Nolen-Hoeksema 1987).

Cognitive Model of Depression

According to the cognitive model of depression (Beck 1976), individuals become depressed because of inaccurate information processing that causes them to interpret events in a biased way. These negative but incorrect beliefs involve negative views of self, a negative world view, and pessimistic future expectations. These beliefs lead to behaviors that serve to reaffirm the beliefs. Furthermore, once they become depressed, individuals tend to focus selectively on negative thoughts, which cause them to perceive themselves and their situation in the worst possible light. This negative bias contributes to the maintenance of the depressed mood (Hollon & Garber 1988). Negative cognitions are viewed as necessary but not sufficient to trigger depression. They interact with other predisposing factors such as genetics, developmental factors, and traumatic events to trigger depression in certain individuals.

Gender Differences in Depression

The incidence of unipolar depression in women is approximately twice as high as the rate in men. According to Nolen-Hoeksema (1987), women tend to ruminate in response to depressed mood, amplifying and sustaining it, and men tend to cope with depressed mood by engaging in active behavior, which serves to inhibit their dysphoria. These differences in coping style may stem from social pressure on men to be active and ignore their moods, whereas women are socialized to be emotional and contemplative (Nolen-Hoeksema 1987).

Rumination contributes to depression by interfering with problem-solving behavior, which can lead to failure, feelings of helplessness, and exacerbation of the depressed mood. In contrast, active behavior can increase feelings of control, create reinforcement, and dampen depression. Furthermore, rumination increases an individual’s focus on negative memories, and activates depressive explanations of the negative feelings, which in turn lead to decreased activity, increased chances of subsequent failure, and a perpetuation of feelings of depression and helplessness (Nolen-Hoeksema 1987).

Interpersonal Factors and Social Skills

Another factor believed to be important in buffering an individual from the effects of loss and other stressful life events is social support. Having few supportive social relationships, a small social network, and few close relationships are associated with increased depression. In addition, there is evidence to suggest that the supportiveness of the most intimate relationship plays the biggest role in buffering an individual from depression, and that other supportive relationships cannot make up for deficiencies in one’s closest relationship (Coyne et al 1991).

Depression arises when negative life events lead to disappointment in expectations, personal goals, or plans. Marital discord is one example of such a stressor. Hammen (1991) has conducted longitudinal research in which she investigated individuals who were achievement focused and individuals who were socially focused. She found that individuals who experienced a life event that was considered a setback in the area of self-esteem focus were more likely to become depressed than those who experienced a setback in a domain that they were less invested in. One of the risk factors for depression is whether an individual experiences a negative life event that leads to a loss of self-esteem in an important area (e.g. an individual who derives most of her self-esteem from interpersonal relationships may become depressed when she experiences marital difficulties with her partner).

The negative life event may, in turn, cause the individual to experience reduced positive reinforcement and an increase in negative mood.

The negative experience can trigger a negative self-focus that leads to self-criticism, unfavorable evaluations of one’s own performance, blaming oneself for negative events, and negative expectations for the future.

There are behavioral consequences of self-focused attention, such as social withdrawal and interpersonal difficulties. Moreover, negative expectations may cause decreased effort and persistence on tasks. The overall effect of the self-esteem-damaging event can create conditions that perpetuate depression (Lewinsohn et al 1985).

Coping skills, such as the ability to see setback as opportunity (e.g. individuals who view losing their job as an opportunity to find a better job), can buffer the individual from loss of self-esteem. In addition, individuals who are able to decrease their self-focus by engaging in a distracting activity may be able to activate problem-solving skills rather than becoming caught up in rumination. Therefore, individuals who have predisposing characteristics (e.g. a confiding relationship or high learned resourcefulness) that permit them to cope effectively with a stressor will be able to stop the depressed feelings before they lead to a depressive episode, whereas those who lack these immunity factors or who have vulnerability factors may not be able to interrupt the depression feedback loop.

There is a complex interaction between predisposing characteristics and negative life events such that the presence of certain immunities may protect an individual from depression in spite of other vulnerability factors and, conversely, a particular combination of vulnerabilities may counteract the positive effect of an immunity factor. An individual’s predisposing characteristics, both immunities and vulnerabilities to depression, mediate the reaction to stressful life events so that in some individuals these events lead to a disruption in expectations or plans and create depression, whereas other individuals can compensate for losses and interrupt the path to depression.

Biological Theories

Research suggests that both psychological and biological factors are important in contributing to the onset of depression. People who are depressed often show signs of dysregulation of circadian rhythms (e.g. greater depression at certain times of the day), sleep disturbance, and alteration of eating habits. Psychological events can trigger this dysregulation and the depression that follows may be accompanied by altered psychological thought processes as well as maladaptive biological changes (Shelton et al 1991). It can be challenging, however, to establish whether depression is linked to a particular event. Even when there is a precipitating event, this can change as the depression continues. There are frequently clear triggers for an initial episode of major depression but not for later episodes (Brown et al 1994). Currently there is no solid evidence that certain types of depression are caused ‘biologically’ and others ‘psychologically’, and there is some evidence to the contrary (Rush & Weissenburger 1994). There is, however, evidence that treatments that alter biological rhythms, such as sleep deprivation, decreasing time spent in rapid eye movement (REM) sleep, and receiving light therapy, can relieve symptoms in many depressed individuals (Shelton et al 1991). These findings led to the development of the dysregulation hypothesis of depression.

Depression as Dysregulation

Individuals have `zeitgebers’ (time-givers): personal relationships, social demands, and behaviors that keep biological rhythms regulated normally. For example, one has to wake up at a certain time to go to work. Ehlers et al (1988) believe that these social interactions are the important link between psychological and biological aspects of depression. If a person loses social reinforcement — perhaps through death of a loved one or loss of a job — there is a resulting dysregulation of biological rhythms resulting in symptoms (e.g. mood disturbance, sleep disturbance, eating disturbance, psychomotor changes, and fatigue) that we call depression. In addition, treatments that reset the ‘biological clock’ are effective in alleviating depression in many individuals. Moreover, there are high rates of depression in people who work swing shift or night shift, who are more likely to experience disturbances in their biological rhythms.

Genetics

There is a hereditary component contributing to the predisposition to develop a mood disorder. Family studies demonstrate that first-degree relatives of those with major depressive disorder are 1.5-3 times more likely to develop depression than the general population. The risk for first-degree relatives of patients with bipolar disorder is 10 times the risk for the general population (Strober et al 1988).

Twin studies indicate that bipolar disorder is more heritable than major depressive disorder. In addition, the fact that there is a higher concordance rate between monozygotic (identical) twins than between dizygotic (fraternal) twins for major depression (40% versus 11%) and bipolar disorder (72% versus 14%) supports the heritability of depression in general (Allen 1976). An adoption study conducted by Mendlewicz & Ranier (1977) found that 31% of biological parents of bipolar adoptees had mood disorders, compared with 2% of the bio-logical parents of normal adoptees. Another study (Wender et al 1986) found that biological relatives of those with a broad range of mood disorders were eight times more likely to have major depression than biological relatives of individuals who were not diagnosed with any mood disorders.

Neurotransmitter Function

It has been hypothesized that abnormal levels of, or function of, neurotransmitters such as norepinephrine (NE), dopamine, and serotonin are a possible cause of depression. It was originally believed that decreased levels of NE contributed to the development of depressive symptoms. This is unlikely to be the mechanism, however, because most antidepressant medications take several weeks to have an impact on depression, but they have an immediate effect on blocking the reuptake of NE and other neurotransmitters. Research suggests that antidepressants may work by increasing the sensitivity of the postsynaptic receptors for NE, which appear to be under-sensitive in depressed individuals (Siever & Davis 1985). Furthermore, research indicates that serotonin dysregulation is also involved in the onset of depression. L-Tryptophan, an amino acid involved in the synthesis of serotonin, is an effective treatment for both mania and depression (Prange et al 1974). Prange and col-leagues have proposed a combined norepinephrine—serotonin hypothesis which states that: (1) a serotonin deficiency increases vulnerability to mood disorder, and (2) when there is a serotonin deficiency, too much NE will result in mania, and too little NE will trigger depression (Prange et al 1974).

Psychological Treatments

The most widely used treatments for depression include psychotherapy and antidepressant treatment. Until recently, antidepressants were considered to be a more effective treatment than psychotherapy. Psychotherapy, however, appears to produce outcomes equivalent to those obtained with antidepressants (Elkin et al 1989), and with fewer side effects. In addition, there is some evidence that psychotherapy may protect against or delay relapsing after treatment has stopped (Evans et al 1992).

When choosing a treatment for a patient, it is important to keep in mind his or her preferences and personality characteristics. Individuals are more likely to respond to a preferred treatment because they believe that it will work, and are less likely to discontinue the treatment. Certain individuals may be more likely to respond to one or another treatment, although the current state of knowledge does not assist in selecting the most effective treatment on the basis of assessing patient characteristics.

Interpersonal Psychotherapy

IPT is directed towards helping individuals interact more effectively with others. It focuses on the individual’s history of maladaptive behaviors that have created negative interactions, and seeks to alter those behaviors, thoughts, and feelings in order to result in more positive relationships. It also looks for links in the present behavior to past experiences in childhood that may have caused the patient to learn those ineffective social skills. Together, the patient and therapist explore the problems and attempt to alter the behavior and consequently relationships over time (Ehlers et al 1988). Research suggests that IPT is an effective treatment for depression and is as effective as antidepressant treatment and other forms of psychotherapy (Elkin et al 1989).

Cognitive Therapy

Cognitive therapy aims to change patients’ maladaptive belief systems to create more acceptable reactions to people and healthier interpretations of situations (Ehlers et al 1988). The patient and therapist explore the patient’s negative beliefs and the patient engages in hypothesis-testing activities to disconfirm his or her erroneous views (Hollon & Garber 1988).

The patient and therapist engage in a dialogue to define the problem, help the patient identify his or her assumptions, determine the importance of events to the patient, and point out the disadvantages of retaining the biased beliefs and maladaptive behaviors. The patient develops new skills that teach him or her to alter negative thoughts and become more independent (Corsini & Wedding 1989).

The main goal of cognitive therapy is to teach patients to alter their faulty information processing so that they interpret events in an adaptive way. The therapist aims to help patients develop new skills which they can use to prevent a recurrence of the depression. In final sessions the patients are asked to imagine themselves in difficult situations and decide what they would do if such an instance arose (Hollon & Garber 1988). Research suggests that cognitive therapy is as effective as antidepressant treatment and other forms of psychotherapy in treating depression (Elkin et al 1989).

Biological Treatments

Antidepressant Treatment

Tricyclic medications are commonly used to treat depression (e.g. imipramine and amitriptyline). The mechanism of tricyclic agents is to block the reuptake of neurotransmitters (especially NE and dopamine) from the space between the neurons in the brain (synaptic cleft). Numerous controlled double-blind research studies have demonstrated that tricyclics have efficacy in the treatment of depression (Goodwin 1992). Like most antidepressant medications, tricyclics take approximately 2-3 weeks to affect the depression (Delgado et al 1992).

Monoamine oxidase inhibitor (MAOI) antidepressants began to be used about the same time as tricyclics, but they are not as widely used. MAOIs may cause high blood pressure when used in conjunction with foods that contain tyramine (e.g. cheese and chocolate). Some early research indicated that they are not as effective as tricyclics; however, a recent review concluded that when used with a proper diet they are an effective treatment for depression (Larsen 1991).

Selective serotonin reuptake inhibitors (SSRIs; e.g. Prozac and Zoloft) are a relatively new class of drugs synthesized in the early 1980s. They work by blocking the reuptake of serotonin so that increased levels remain in the synaptic cleft. They have a high selectivity for blocking serotonin reuptake receptors, whereas tricyclics affect to a greater extent both NE and other neurotransmitters. SSRIs are currently the most frequently prescribed medication. Controlled trials suggest that they are equivalent in effectiveness to the tricyclics; however, they have fewer side effects, are more easily adjusted to the proper dosage level, and are less toxic if the patient overdoses (Greenberg & Fisher 1997). Table 3 summarizes each type of medication, side effects, and mechanism of action.

Electroconvulsive Therapy (ECT)

ECT is usually administered to inpatients in a series of treatments. Treatment frequency is approximately twice a week. Many people demonstrate marked improvement after six to eight sessions, but some need more. Electrodes are placed either on both sides of the head or at the front and back of the skull on one side of the head. ECT remains an effective treatment according to several studies (Consensus Conference 1985), although the mechanism through which it works is still unknown (Sackheim 1989). ECT is usually reserved for severely depressed patients who have not responded to other forms of treatment or who are at immediate risk of suicide. ECT may also be more effective than medication with rapid cycling bipolar patients and depressed patients with psychotic symptoms. Although infrequent, ECT can result in pervasive and persistent memory loss. More frequently, it results in minor memory loss for events that happen shortly before receiving treatment, but does not result in persistent memory loss.

Some clinicians believe that certain types of depression have a biological etiology and others have a psychological etiology. The literature suggests, however, that there are a number of different possible causes of depression, each involving a complex interaction between biological, psychological, and social factors. No one perspective provides a complete explanation for how depression develops. Regardless of how the episode appears to be precipitated, the causal mechanisms are affected at all three levels: biological, psychological, and social. While medications seem to intervene at a biological level and psychotherapy treats depression at a psychosocial level, both interrupt the chain of events that maintains the depression and both facilitate changes in the other domains. For example, antidepressants affect neurotransmitter receptor sensitivity but also affect how individuals interact with others once they begin to feel better. Psychotherapy initially targets behavior change or cognitive change (e.g. socializing with others or learning not to make minor setbacks into devastating events), which then triggers physiological changes as well.

It is important to remember that the cause of depression cannot be explained with a simple biological or psychological explanation alone. The likelihood that any given individual becomes depressed is the result of a complex interaction of heredity, physiology, environmental events, cognitive representations, and situational factors. Treatment can intervene at any point in this complex web and have effects on function across all arenas. In this early stage of research into the effectiveness of acupuncture, it is important to keep in mind that the impact of acupuncture may be seen in physiological, psychological, and social domains, but that such effects do not address the ultimate question of precisely how acupuncture works in the treatment of depression.

Actions of N-Acetylcysteine in the Central Nervous System – Implications for the Treatment of Neurodegenerative and Neuropsychiatric Disorders

N-Acetylcysteine (NAC) is the N-acetyl derivative of cysteine, and is less reactive, less toxic, and less susceptible to oxidation than cysteine, as well as being more soluble in water. For these reasons it is a better source of cysteine than the parenteral administration of cysteine itself [1]. NAC is rapidly absorbed, with time to peak plasma levels (tmax) being 1.4 ± 0.7 h following oral administration. The average elimination half-life (t1/2) has been reported to be 2.5 ± 0.6 h [2]. The bioavailability of NAC increases according to the dose, with the peak serum level being on average 16 µmol/L after 600 mg and 35 µmol/L after 1200 mg [3]. When taken orally NAC is readily taken up in the stomach and gut and sent to the liver where it is converted almost entirely to cysteine and used for glutathione (GSH) synthesis [4]. Cysteine that is not converted to GSH is capable of crossing the blood–brain barrier by means of sodium-dependent transport systems [5].

The endogenous tripeptide GSH is the most abundant low-molecular-weight thiol in human cells and plays a central role in antioxidant defense from ROS [6] as well as protection against toxic compounds [7]. GSH is synthesized in tissue from the amino acids L-cysteine, L-glutamic acid, and glycine, where the availability of cysteine is generally the rate-limiting factor in its production [8]. Across a number of studies, supplementation using NAC has been found to be an effective way of increasing intracellular GSH levels, in clinical cases of deficiency [9–11] as well as amongst healthy volunteers [12]. Due to its effectiveness in raising GSH levels and protecting the human body from oxidative stress and toxins, NAC supplementa-tion has been investigated as a treatment for a wide number of conditions including paracetamol intoxication, HIV, cancer, radiocontrast-induced nephropathy, and chronic obstructive pulmonary disease [6]. There is evidence to suggest that in Alzheimer’s disease (AD), GSH levels are decreased in both cortical areas and the hippocampus [13]. For this reason NAC may play a neuroprotective role by restoring GSH levels to a normal state.

In vitro research by Chen and colleagues [14] revealed that pretreatment of cortical neurons with NAC protected mitochondrial function and membrane integrity under conditions of oxidative stress. Similarly, Olivieri and colleagues [15] found a neuroprotective effect for NAC in neuroblastoma cells exposed to oxidative stress. Pretreatment with NAC resulted in a reduction in oxidative stress resulting from exposure to amyloid-O proteins, as well as a reduction in phosphotau levels. Research by Martinez and colleagues [16] revealed that aged mice fed NAC for 23 weeks performed better on a passive avoidance memory test than age-matched controls. Furthermore, lipid peroxide and protein carbonyl contents of the synaptic mitochondria were found to be significantly decreased in the NAC-supplemented animals compared to the controls.

Mice deficient in apolipoprotein E undergo increased oxidative damage to brain tissue and cognitive decline when maintained on a folate-free diet. Tchantchou et al. [17] found that dietary supplementation with NAC (1 g/kg diet) alleviated oxidative damage and cognitive decline, and restored GSH synthase and GSH levels to those of normal mice. There is also evidence to suggest that NAC supplementation may

bring about a reduction in amyloid-O formation. In an animal model of AD using 12-months-old SAMP8 mice with an overexpression of the amyloid precursor pro-tein, Farr et al. [18] found chronic administration of NAC to bring about significantly improved memory performance on the T-maze avoidance paradigm and lever press appetitive task. In an animal model of AD using TgCRND8 mice, Tucker et al. [19] found chronic treatment of NAC for 3 months to result in a significant reduction of amyloid-O in cortex. Similarly, research by Fu et al. [20] revealed that mice with amyloid-O peptide intracerebroventricularly injected performed significantly better in behavioral tests of memory and learning when pretreated with NAC in compari-son to those without pretreatment. NAC pretreatment was also found to significantly reverse reductions in GSH and ACh.

While considerable experimental evidence exists for the neuroprotective role of NAC, there is currently a scarcity of clinical studies examining its efficacy in the treatment and prevention of dementia. One such study, a double-blind clinical trial of NAC in patients with probable AD was conducted by Adair and colleagues [21]. Forty-three patients were randomized to either placebo or 50 mg/kg/day NAC for 6 months and tested at baseline as well as at 3 and 6 months on MMSE as well as a cognitive battery. NAC supplementation was not found to be associated with significant differences in MMSE scores compared to placebo at either 3 or 6 months; however, patients receiving NAC showed significantly better performance on the letter fluency task compared to placebo, as well as a trend toward improvement in performance on the Wechsler memory scale immediate figure recall test. Further, ANOVA using a composite measure of cognitive tests favored NAC treatment at both 3 and 6 months.

In a 12 month open-label study of the efficacy of a nutraceutical and vitamin formulation in the treatment of early-stage AD, Chan et al. [22] administered 600 mg of NAC daily as part of a larger formulation of substances including ALCAR, alpha-tocopherol, B6, folate, and S-adenosyl methionine to 14 community-dwelling individuals. Participants were found to be significantly improved on the dementia rating scale (DRS) at both 6 and 12 months, with an overall improvement of 31%. However, a limitation of this study was that no placebo group was used for comparison, although the authors claim that the efficacy of their nutraceutical formulation exceeded that of historical placebos in previous studies of mild-to-moderate AD. In a follow-up study by the same group [23], the efficacy of the same nutraceutical formulation containing NAC was tested in a group of 12 nursing home residents with moderate to late-stage AD over a 9 month period. This time participants were randomized to either treatment or placebo. The nutraceutical formulation was found to delay cognitive decline as measured by the DRS for approximately 6 months, whereas in the placebo group a similar rate of decline was observed at only 3 months. While it is difficult to differentiate the efficacy of NAC from the other substances included in the formulation, these studies provide preliminary evidence for the efficacy of NAC in improving symptom severity in early-stage AD, and delaying the onset of decline in moderate to late-stage AD.

Group II metabotropic glutamate receptors (mGluR2/3) are located presynaptically on neurons in a large number of brain regions including the cortex, amygdala, hippocampus, and striatum [24], and play an important role in the regulation of the synaptic release of glutamate [25]. Stimulation of mGluR2/3 receptors by extracellular glutamate has an inhibitory effect on the synaptic release of glutamate [26]. Extracellular levels of glutamate are maintained primarily by means of the cystine–glutamate antiporter [27]. This Na+-independent antiporter is bound to plasma membranes and is found ubiquitously throughout the body, while being located predominantly on glial cells in the human brain [28]. Cystine is the disulfide derivative of cysteine, consisting of two oxidized cysteine residues. When extracellular levels of cystine are increased in the brain, the antiporters on glial cells exchange extracellular cystine for intracellular glutamate. This leads to the stimulation of mGluR2/3 receptors and inhibition of synaptic glutamate release. For this reason, cysteine prodrugs have the ability to reduce the synaptic release of glutamate, with important implications for the treatment of psychiatric disorders.

INHIBITION OF GLUTAMATE RELEASE IN OBSESSIVE COMPULSIVE DISORDER

A number of magnetic resonance spectroscopy (MRS) studies of obsessive compulsive disorder (OCD) have revealed abnormal glutamate transmission in brain regions associated with cortico-striatal-thalamo-cortical (CSTC) neurocircuitry. Glx, a composite measure of glutamate, glutamine, homocarnosine, and GABA, has been found to be elevated in the caudate in OCD patients and to normalize again following SSRI treatment [29–33]. This finding is consistent with the metabolic hyperactivity in CSTC circuits, which is a known hallmark of OCD [34]. In contrast, Glx levels have been found to be decreased in the anterior cingulate [35], a finding that parallels the inverse relationship between anterior cingulate and basal ganglia volume in OCD patients [36]. Further evidence of elevated glutamate levels associated with OCD comes from a study by Chakrabarty et al. [37], who reported increased levels of glutamate in the CSF of drug-naive OCD patients.

A number of studies have investigated the effects of glutamate-modulating drugs in the treatment of OCD spectrum disorders. In an open-label study using Riluzole, a pharmacological agent which reduces synaptic glutamate release, Pittenger et al. [38–39] reported a significant decrease in symptoms in 13 treatment-resistant OCD patients over a 12 week period. However, it has been found that not all anti-glutamatergic agents have been found to be effective, with topiramate (Topamax) being found to exacerbate OCD symptoms and Lamotrigine found to be ineffective [36]. There have also been mixed results found to date for the efficacy of memantine in the treatment of OCD [40]. This is most likely due to differences in the mechanism of action associated with each of these varied compounds.

Due to the effects of inhibiting synaptic glutamate release through glial cystine– glutamate exchange, NAC also been investigated as a possible treatment for OCD. In a case study of a 58 year-old woman with SRI-refractory OCD, Lafleur et al. [41] reported that NAC augmentation of fluvoxamine resulted in a marked reduction in OCD symptoms (Y-BOCS), and a clinically significant improvement in OCD symptoms. The NAC dose used in this study was titrated up from 1200 mg PO daily to 3000 mg daily over a 6 week period, and then maintained at this dosage level for a further 7 weeks. It is interesting to note that a reduction of 8 points on the Y-BOCS scale was noticed after only 1 week of treatment, which is indicative of rapid onset of treat-ment effects in comparison to conventional SSRI treatments for OCD, which may take several weeks for effects to become noticeable [42]. The possibility is also raised that there are acute effects associated with NAC use, whereby a patient with OCD may be able to use NAC on as-needed basis as an augmentation strategy for days when their symptoms are worse than usual. Two clinical trials are currently underway to test the efficacy of NAC in the treatment of OCD. Costa and colleagues from the University of Sao Paulo are conducting a 16-week intervention study using 3000mg/day NAC as an adjunctive treatment in OCD (NCT01555970) while Pittenger and colleagues from Yale University are conducting a 12-week study using 2400mg/day NAC for children aged 8–17 years (NCT01172275). It is hoped that these studies will provide important data as to the efficacy of NAC as treatment strategy for OCD.

A disorder related to OCD, which is classified as part of the OCD spectrum dis-orders is trichotillomania, characterized by repetitive hair pulling. Grant et al. [43] conducted a double-blind trial to assess the efficacy of NAC (1200–2400 mg/day) in 50 participants with trichotillomania over a 12 week period. Patients in the NAC treat-ment group were found to have significantly greater reductions in hair-pulling symptoms in comparison to placebo. Significant improvements were observed from 9 weeks of treatment onwards. Fifty-six percent of patients were found to be “much or very much improved” from the NAC treatment group in comparison to only 16% assigned to the placebo group. Another OCD spectrum disorder that NAC use has been investigated as a potential treatment strategy is compulsive nail-biting. Berk et al. [44] present three case studies where patients with a life-long history of compulsive nail-biting were found to benefit from NAC treatment. In the first case study, a 46 years old woman is reported to stop nail-biting altogether over a 7 months period using a dosage of 1000 mg NAC BID. In the second case study, a 44 years old woman is reported to stop nail biting after 4 months of treatment with NAC 1000 mg BID, and to have not recommenced on a 2 month follow-up. In the third case study, a 46 years-old patient was not reported to stop nail-biting all together, but noticed a reduction in this behavior after 28 weeks after starting NAC treatment. In addition to trichotillomania and nail-biting, NAC has also been reported to be effective in the reduction of skin-picking behavior [45].

A number of concerns will need to be addressed in assessing the suitability of NAC as a viable treatment option for OCD and related disorders, beyond a demonstration of efficacy. Considering the high degree of comorbidity of depression with OCD [46], it is necessary in further research to investigate the effects of NAC on mood. Although preclinical evidence to date is promising, it suggests that agonist acting on the mGluR2/3 receptors may dampen responses to stress and have a potential antidepressant effect [47–48], and the case study by Lafleur et al. [41] also reported a decrease in depression in their patient as measured by the HAM-D over the course of the trial. It may be important to monitor possible acute side effects of cognitive slowing that may result from over-regulation of glutamatergic tone with high-dose NAC use, as has been occasionally reported in relation to Riluzole [49].

Increased glutamate transmission in the nucleus accumbens has been found to be a mediator of drug-seeking behavior, while in the case of repeated use of drugs of abuse such as cocaine, a reduction in basal levels of extracellular glutamate in the nucleus accumbens are also observed [50,51]. Alterations in cystine–glutamate exchange and metabotropic glutamate receptor activity has also been found to regulate vesicular release of dopamine, another central neurotransmitter in reward-related behavior [26,52]. Due to its effects in inhibiting the synaptic release of glutamate in the CNS, NAC has been investigated for use in the treatment of substance abuse. Preclinical research by Baker et al. [52] revealed that systemic administration of NAC to cocaine-treated rats restored extracellular glutamate levels in the nucleus accumbens in vivo. Further, due to its effects on stimulating cystine–glutamate exchange, NAC was found to block cocaine-primed reinstatement of drug-taking behavior. In rats withdrawn from cocaine use, there is a change in the ability to create synaptic plasticity, which is related to alterations in prefrontal glutamatergic innervation of the nucleus accumbens core. Moussawi et al. [53] reported that the administration of NAC to cocaine-treated rats reversed the deficit in synaptic plasticity by indirect stimulation of mGlu2/3 and mGlu5 receptors, responsible for long-term potentiation and long-term depression, respectively.

In a pilot study investigating the effects of NAC on craving in 15 cocaine-dependent humans, LaRowe et al. [54] reported that 600 mg NAC administered at 12 h intervals over a 3 day period resulted in a significant reduction in the desire to use cocaine, interest in cocaine and cue viewing time, in the presence of cocaine-related cues. An open-label dose-ranging study of NAC in the treatment of cocaine dependence in humans was conducted by Mardikian et al. [55]. Twenty-three treat-ment-seeking cocaine-dependent patients were assigned to either NAC 1200, 2400, or 3600 mg/day over a 4 week trial. Sixteen of the patients completed the trial, and the majority of these either stopped using cocaine or significantly reduced their intake by the end of the trial. The higher doses of 2400 and 3600 mg/day were found to be more effective in treating cocaine-dependence, with higher retention rates in comparison to the lower dose of 1200 mg/day.

In human research using other drugs of abuse, similar results have been reported. In an open-label study investigating the use of NAC in cannabis addiction, Gray et al. [56] reported that 1200 mg NAC twice daily resulted in significant reductions in marijuana craving amongst 24 cannabis-dependent participants, as well as a trend-level reduction in marijuana usage, over a 4 week period. Knackstedt et al. [57] conducted a study to investigate the effect of nicotine on cystine–glutamate exchange in the nucleus accumbens and the efficacy of NAC in the treatment of nicotine addiction, using both animal and human data. Over a 21 day period, rats self-administered nicotine intravenously and 12 h following the last nicotine dose the brains were removed and immunoblotting was conducted in order to investigate changes in the catalytic subunit of the cystine–glutamate exchanger (xCT) or the glial glutamate transporter (GLT-1) in the nucleus accumbens, the ventral tegmental area (VTA), the amygdala, and the PFC. Decreased expression of the xCT was observed in the nucleus accumbens and the VTA, and decreased GLT-1 expression was observed in the nucleus accumbens. In the second part of the study, 29 nicotine-dependent human subjects were administered 2400 mg NAC/daily versus placebo for 4 weeks in a double-blind design. Smokers treated with NAC were found to report a greater reduction in the number of cigarettes smoked over the 4 week period in comparison to placebo, with a significant time × treatment group interaction when controlling for alcohol consumption.

Preclinical studies have demonstrated that levels of glutamate in the nucleus accumbens mediate reward-seeking behaviors in general [58], not only addictive behaviors related to pharmacological agents. A pilot study by Grant et al. [59] investigated the efficacy of NAC in the treatment of pathological gambling. Twenty-seven pathological gamblers were administered NAC over an 8 week period in an open-label design, start-ing with an initial dose of 600 mg/day that was titrated up over the first 4 weeks until a noticeable clinical improvement was seen, with a maximum possible dose being 1800 mg/day. The Yale-Brown obsessive compulsive scale modified for pathological gambling (PG-YBOCS) was used as the primary endpoint. PG-YBOCS scores were found to be significantly decreased by the end of the 8 weeks, with a mean effective NAC dose of 1476.9 ± 311.13 mg/day. Sixteen participants were classified as responders, defined by a 30% or greater reduction in PG-YBOCS score. Of these, 13 participants entered a double-blind follow-up phase, where they were randomized to either continue receiving their maximum dose from the open-label phase versus placebo over a 6 week period. At the end of the double-blind phase, 83.3% of the NAC group still met responder criteria in comparison to only 28.6% of those assigned to placebo. Although the first of its kind, this well-designed pilot study provides preliminary data in support of the efficacy of NAC in the treatment of pathological gambling.

A longer-term study by Bernardo et al. [60] investigating the effect of 2 g/day NAC on the use of alcohol, tobacco, and caffeine use in patients with bipolar disorder failed to find efficacy for NAC. Seventy-five participants were randomized to NAC or placebo over a 6 month period, with no significant changes in substance use observed over the length of the trial, with the exception of reduced caffeine intake in the NAC group at week 2. However, it is important to note that patients were selected for the study on the basis of clinical criteria for bipolar disorder, rather than a primary substance abuse disorder. For this reason, there were low rates of substance use in the cohort, which detracted from the statistical power necessary to determine a treatment effect.

CSF levels of GSH have been found to be decreased by 27% in drug-naive schizophrenia patients, while MRS has revealed that levels in the medial PFC are reduced by as much as 52% [61]. Decreased levels of GSH have also been reported in the caudate region in schizophrenia patients, as revealed by post-mortem assay [62]. There is evidence to suggest that decreased levels of GSH in schizophrenia are due to genetic polymorphisms in the genes responsible for GSH synthesis [63,64]. Due to the efficacy of NAC in boosting GSH levels in the CNS, it has been investigated for possible clinical benefits in the treatment of schizophrenia. Berk et al. [65] administered NAC 2000 mg/day versus placebo over a 6 month period to 140 patients with chronic schizophrenia, as augmentation to their regular antipsychotic medication. Patients receiving NAC were found to have a significant reduction in negative symptoms of schizophrenia as measured by the positive and negative symptoms scale (PNSS) as well as a reduction in clinical global impression of symptom severity (CGI-S) and CGI-improvement. These findings are corroborated by the research of Lavoie et al. [66], which has demonstrated that chronic NAC use at 2000 mg/day over 60 days improves mismatch negativity, a measure of NMDA receptor function, in schizophrenia patients. While the reason why restoring GSH levels and reducing oxidative stress in the brain brings about a clinical improvement in the negative symptoms of schizophrenia remains to be elucidated, these findings provide encouraging preliminary evidence for the efficacy of NAC as an augmentation strategy in treating this disorder.

Alterations in GSH metabolism have also been described as a feature of bipolar disorder as well as schizophrenia [67–69]. By applying the same rationale to bipolar disorder, Berk et al. [70] investigated whether boosting GSH levels through NAC supplementation would improve depressive symptoms in this disorder. Using a randomized controlled study design 75 individuals with bipolar disorder were administered NAC 2000 mg/day versus placebo over a 6 month period. NAC treatment was found to be associated with a significant improvement on the Montgomery Asberg depression rating scale (MASRS) after 20 weeks. The authors hypothesized that the clinical improvement could be attributed to the restoration of oxidative imbalances that are perturbed in bipolar disorder.

Oral doses of NAC up to 8000 mg/day have not been known to cause clinically significant adverse reactions [10], and in a review of over 46 placebo-controlled tri-als, with NAC administered orally to a total of 4000 people, no significant adverse effects from NAC treatment were observed [4]. In relation to high oral doses of NAC (around 10,000 mg) typically used in cases of acetaminophen overdose, a review by Miller and Rumack [71] reported that mild symptoms such as headache, lethargy, fever, or skin rash occur in around 1%–5% of patients, while more moderate symptoms such as increased blood pressure, chest pain, hypertension, rectal bleeding, and respiratory distress occur in less than 1% of patients. One potential cause for concern over NAC supplementation was raised in a study by Palmer et al. [72] where rats receiving high-dose NAC in vivo for 3 weeks developed pulmonary arte-rial hypertension (PAH). The authors linked the finding of PAH to the conversion of NAC to S-nitroso-N-acetylcysteine (SNOAC) and a resultant hypoxia-mimetic effect. However, it is important to note that the rats were continuously exposed to a dose per weight roughly 40 times higher than the dose typically used in human studies. Good manufacturing practice (GMP) is important for NAC to ensure minimal oxidization to its dimeric form (di-NAC). Di-NAC is pharmacologically active at very low concentrations, and has immunological effects opposite to that of NAC [73]. For this rea-son it is important that any NAC obtained for chronic usage is from a trusted source.

NAC is a substance with the potential to treat a diverse range of neuropathologies (see Table below for a summary of clinical research). In whole NAC is well tolerated, with a low incidence of adverse events in the dose ranges typically required for clinical effects. As a highly effective cysteine prodrug, NAC can both significantly boost endogenous GSH production and influence the synaptic release of glutamate due to its effects on cystine–glutamate exchange. For these reasons, NAC can be used as a means of ameliorating symptoms in wide range of disorders of the CNS including neurodegenerative disorders as well as obsessive-compulsive spectrum disorders, substance abuse disorders, behavioral addictions, schizophrenia, and bipolar disorder. Further large-scale trials of NAC are warranted in order to better establish clinically effective dosage ranges and treatment schedules for these varied neurodegenerative and neuropsychiatric conditions.

AD, Alzheimer’s disease; CGI, clinical global impression; DRS, dementia rating scale; MADRS, Montgomery Asberg depression rating scale; OCD, obsessive compulsive disorder; PANSS, positive and negative symptoms scale; PG-YBOCS, Yale-Brown obsessive compulsive scale modified for pathological gambling; RCT, double-blind randomized placebo-controlled trial; Y-BOCS, Yale-Brown obsessive compulsive scale.

Evaluar la utilidad de Bacopa monnieri para tratar los neurobiológicos y cognoscitivo procesos de apuntalamiento cognitivo envejecimiento

With increasing life expectancies and the maturation of the “baby boom” generation, adapting to the challenges posed by the aging population has been identified as one of the major issues facing contemporary Australian society (Australian Productivity Commission, 2005). For Australia, like many Western nations, human aging has significant societal, economic, health, and, importantly, personal costs. In purely economic terms, the costs of aging reflect decreased productivity as well as increased levels of reliance on public services to health and social support but this also has obvious ramifications for older citizens’ ability to lead fulfilling lives. Increasing age is associated with a cluster of illnesses involving oxidative stress, cardiovascular and respiratory disease, and, importantly, neurological conditions such as Parkinson’s disease and Alzheimer’s disease. The New Zealand Treasury has estimated that the cost to the public health system alone of individuals over 65 years of age is five times that of people under 65 (Bryant and Sonerson, 2006). The same report concludes that 33% of these increased costs could be offset by measures aimed at maintaining improved health, which of course also involves brain and cognitive processes.

A time-honored and much empirically supported method of promoting optimal health throughout the life span has been through the adoption and maintenance of an appropriate, healthy diet. Recent research suggests that this principle not only applies to protection from “physical ailments” such as cardiovascular problems, but may also extend to ameliorating the effects of cognitive decline associated with increased age. The maintenance of brain health underpinning intact cognition is a key factor to maintaining a positive, engaged, and productive lifestyle. In the light of this, the role of diet including supplementation with nutritional and even pharmacological interventions capable of ameliorating the neurocognitive changes that occur with age constitutes vital areas of research.

Individual age-related changes in cognition vary greatly. However, research in cognitive aspects of aging (typically in 60–90 year-olds) has identified consistent deficits in reasoning and decision making, spatial abilities, perceptual-motor and cognitive speed, and, most robustly, memory (e.g., Christensen and Kumar, 2003). Longitudinal studies of aged populations illuminate the time course of cognitive deterioration. Using 5–10 year retest intervals, significant decrements across most cognitive capacities become evident. A recent review of longitudinal aging studies concludes that crystallized intelligence (e.g., factual knowledge) remains intact until late aging whereas measures of speed, information processing, and aspects of memory (e.g., working memory) are more sensitive to decline from age 60 (Christensen and Kumar, 2003).

Neuroimaging studies reveal that increasing age is reliably associated with ventricu-lar enlargement, reduction in gross brain volume, reductions in frontal and temporo-parietal brain volume, higher levels of cortical atrophy, and increased white-matter hyperintensities (Looi and Sachdev, 2003). Ultimately, shrinkage of cortical volume reduces cognitive capacity (MacLullich et al., 2002), and age-related increases in neuropathological events such as ß-amyloid protein deposition and formation of neurofibrillary tangles represent significant risk factors. Neuropathological events such as ß-amyloid deposition are not exclusive to neurodegenerative disorders such as AD, in fact occurring in a large proportion of cognitively intact individuals. For example, in one study, the proportion of nonclinical subjects with ß-amyloid deposits ranged from 3% in a 36–40 age group to 75% in an 85+ age group (Braak and Braak, 1997). Alongside age-associated cortical degeneration (MacLullich et al., 2002), there exist numerous microscopic insults related to oxidative stress. Free radicals formed in the brain produce significant cellular damage and mediate processes that result in neural cell death on large scales (Packer, 1992). Between 95% and 98% of free radicals and reactive oxygen species (ROS), O2-, HO, and H2O2 are formed by mitochondria as by-products of cellular respiration. Studies of mitochondria isolated from the brain show that 2%–5% of total oxygen consumed yields ROS, and these highly reactive molecules make a significant contribution to the peroxidation of principal cell structures (e.g., membrane lipids) (Papa and Skulachev, 1997). Brain tissue is particularly susceptible due to its disproportionately high metabolic rate and levels of oxygen, the cytotoxic actions of glutamate, and its high concentrations of peroxidizable unsaturated fatty acids (Packer, 1992). Aging decreases the brain’s ability to combat the actions of free radicals. Aging is associated with increased levels of pro-oxidant mediators and decreases in antioxidants (Artur et al., 1992). The relationship between cognition and oxidative stress is evident in the extensive damage caused by free radicals in age-related neurological conditions (Coyle and Putfarcken, 1993; Smith et al., 1996) and animal models of age-related oxidative injury with central cognitive and behavioral impairments (Forster et al., 1996). Concurrent with the normal age-related cognitive changes are increases in the formation of brain ROS resulting in significant damage to DNA, proteins, and in particular membrane lipids (Smith et al., 1991). Although multiple factors precipitate oxidative stress throughout the body, the brain is particularly vulnerable, and its cumulative effects may account for the delayed onset and progressive nature of Alzheimer’s and Parkinson’s demen-tias as well as normal age-related mental deterioration (Coyle and Putfarcken, 1993).

The central role of oxidative stress in age-related cognitive decline and neurodegenerative diseases has driven numerous studies examining the potential benefits of antioxidants in altering, reversing, or forestalling neuronal and behavioral changes (e.g., Sano et al., 1997). Antioxidant supplementation results in improved cognition and behavior in aged animals and concurrent decreases in oxidative insult to neural structures (Socci et al., 1995). Human research in this area is largely limited to epidemiological studies. These have identified positive associations in aged individuals between biological levels of dietary antioxidants (vitamins E and C) and working memory measures including the Wechsler Memory test (Goodwin et al., 1983). Less reliable than biological measures, large-scale studies (3000+ participants) have also identified positive relationships between dietary intake of vitamins C and E and standardized memory measures (Masaki et al., 2000). While these nonclinical trials do not demonstrate causality, the consensus that memory is the main cognitive variable affected by antioxidant status is consistent with patterns of age-related cognitive decline and the in vivo neuroanatomy of lipid peroxidation (Sram et al., 1993). Three controlled studies of active antioxidant supplementation in aged individuals over periods of 1 year or longer reported improved performance on tests of short-term memory, verbal learning, and nonverbal memory (Sram et al., 1993; La Rue et al., 1997; Chandra, 2001). However, these studies did not incorporate indicators of oxidative stress, making it impossible to determine the role of antioxidants in the cognitive changes. Despite the great promise that antioxidant supplementation holds for understanding age-related mental deterioration, studies published in the area have been methodologically inadequate. In particular, human studies have thus far been severely limited by inappropriate cognitive measures, lack of biochemical indicators, uncontrolled subject populations, and unspecific antioxidant supplementation. One particular herbal medicine that may have some utility in treating pathological changes in the brain associated with age-related cognitive decline and that has been used in our laboratory is Bacopa monnieri (BM).

Bacopa monnieri (BM) is a botanical medicine from India that has been used for over 3000 years as a traditional ayurvedic treatment for asthma, insomnia, epilepsy, and as a “memory tonic” (Russo and Borrelli, 2005). BM has been used in traditional ayurvedic medicine for various indications including memory decline, inflammation, pain, pyrexia, epilepsy, and as a sedative (Russo and Borrelli, 2005). BM contains Bacoside A and bacoside B that are steroidal saponins believed to be essential for the clinical efficacy of the product. While BM has been reported to have many actions, its memory enhancing effects have attracted most attention and are supported by the psychopharmacology literature. Behavioral studies in animals have shown that BM improves motor learning, acquisition, retention, and delay extinction of newly acquired behavior (Singh and Dharwan, 1997). Although the exact mechanisms of action remain uncertain, evidence suggests that BM may modulate the cholinergic system and/or have antioxidant and metal-chelating effects (Agrawal, 1993; Bhattacharya et al., 1999). BM may also have antiinflammatory (Jain, 1994), anxiolytic and antidepressant actions (Bhattacharya and Ghosal, 1998), relaxant properties in blood vessels (Dar and Channa, 1999), and adaptogenic activity (Rai et al., 2003). Chronic administration of BM inhibits lipid peroxidation in the prefrontal cortex, striatum, and hippocampus via a similar mechanism to vitamin E (Bhattacharya et al., 2000). In an animal model of AD, there was a dose-related reversal by BM of cognitive deficits produced by the neurotoxins colchicine and ibotenic acid (Bhattacharya et al., 1999). In rodents, BM inhibited the damage induced by high concentrations of nitric oxide in astrocytes (Russo et al., 2003). Memory deficits following cholinergic blockade by scopolamine were reversed by BM treatment. In animal studies, BM reduced lipid peroxidation induced by FeSO4 and cumene hydroperoxide, indicating that, similarly to the chelating properties of EDTA, it acts at the initiation level by chelating Fe++ (Tripathi et al., 1996). More recently, in transgenic mice, BM supplementation reduced specific amyloid peptides by up to 60% while also improving memory performance (Holcomb, 2006). Thus, BM appears to have multiple modes of action in the brain all of which may be useful in ameliorating cognitive decline in the elderly. These include (1) direct procholinergic action, (2) antioxidant (flavonoid) capacity, (3) metal chelation, (4) antiinflammatory effects, (5) increased blood circulation, (6) adaptogenic activity, and (7) removal of ß-amyloid deposits.

Extracts of BM contain significant levels of saponic bacosides A, B, and C; and bacosapoinins D, E, and F, in addition to other chemical constituents including alka-loids, flavonoids, and phytosterols (Pengelly, 1997; Heinrich et al., 2004). The main chemical constituent of BM is bacoside A, which has been postulated to be responsible for the memory facilitating action of the plant (Russo and Borrelli, 2005). Bacoside A usually cooccurs with bacoside B that differs only in terms of its optical rotation. BM has been available in a standardized form since 1996 for clinical research (Singh and Dhawan, 1997).

Importantly, for both research and the community, the bacoside content does vary between manufacturers, as does the quality of the extract. Thus, clinical evidence from standardized high quality extracts cannot be extrapolated to other extracts. Higher level clinical studies typically use BM with bacoside content standardized to 50%–55%. Currently, most clinical evidence for a cognitive related effect from BM stems from one to two extracts including the extract CDRI08, which has been developed and studied extensively preclinically and in animals by the Indian Government (particularly the CDRI). Progressively, human trials on both CDRI08 and BM are now appearing with a particular emphasis on improving cognitive performance including memory.

A systematic review of the literature (Pase et al., in press) found eight human randomized controlled trials that met entry requirements (i.e., double-blinded, high quality studies). Of these studies, seven used chronic administration of BM while one was an acute study using a single 300 mg dose. No acute studies have to date shown a positive cognitive enhancement although there are current trials underway, and new data may shed some light on this possibility. However, based on the animal and in vitro studies on BM, it seems more likely that the mechanisms to improve cognition will exert influence chronically rather than acutely. Usually, acute cognitive enhancers or nootropic substances exert cognitive benefits via blood flow or direct neurotransmitter release. BM extracts are more likely to exert cognitive enhancement through inflammatory, antioxidant, or even removal of beta amyloid. The exact mechanism(s) are yet to be confirmed although large-scale mechanistic studies are now underway such as the Australian Research Council Longevity Intervention (Stough et al., 2012).

Chronic studies typically utilized a daily dose of 300 mg (standardized for baco-sides) for the duration of the study—nearly all studies use 3 months administration or similar (Stough et al., 2001; Roodenrys et al., 2002; Calabrese et al., 2008; Stough et al., 2008; Morgan and Stevens, 2010). In Roodenrys’ (2002) study, an increased dose of 400 mg/day was given to participants weighing over 90 kg. However, lower (250 mg/day) (Raghav et al., 2006) and higher doses of 450 mg/day (Barbhaiya et al., 2008) have been used chronically.

The human studies reviewed by Pase et al. (2012) provide evidence of highly promising results in areas of cognition, memory, and speed of processing tasks. Some studies used a healthy young adult population (Stough et al., 2001; Nathan et al., 2004; Stough et al., 2008), and others used “middle aged” (Roodenrys et al., 2002) or “elderly” populations (Calabrese et al., 2008). Progressively, aging populations will be targeted for BM supplementation, given current evidence for mode of action on the brain.

Regardless of the age of the population, BM consistently improved selected cognitive functions. For example, BM was shown to improve working memory (Stough et al., 2008), learning rate and memory consolidation, and other components of the Rey Auditory Verbal Learning Test (Stough et al., 2001; Calabrese et al., 2008; Morgan and Stevens, 2010) as well as improvements in memory measured by the Wechsler Memory Scale found in the Raghav et al. (2006) study. Furthermore, exec-utive functioning tasks, such as the stroop (Calabrese et al., 2008) and inspection time (Stough et al., 2001), have also shown to be improved by intervention with BM. The effect sizes on many domains were moderate to strong. BM on various out-come measures consistently improved cognition, memory, and speed of processing in older adults with an overall moderate effect on all measure of memory (mean d = 0.58). BM was also found to improve learning and memory (mean d = 0.61), working memory and executive function (mean d = 0.54), and visual processing and attention (mean d = 0.28).

BM has also been studied in the context of age-associated memory impairment (AAMI). Raghav et al. (2006) tested a sample of middle aged to elderly participants with AAMI. Participants receiving a standardized BM extract (250 mg/day) showed statistically significant improvement across subtests of the Wechsler Memory Scale from week 4 onward. Tasks of mental control, logical memory, and paired associated learning showed the greatest improvement. Clearly, these data are preliminary and need to be replicated. However, they support and reinforce the memory and cognitive enhancing effects of BM as well as an appropriate age-related target for intervention.

To date, only one study has been reported to assess the efficacy of BM in a sample of participants with dementia. A small 6 month pilot study has been carried out by Morgan and colleagues (see Morgan and Stevens, 2010) on participants diagnosed with mild–moderate dementia using BM (300 mg daily) as an adjunct intervention to their standard treatment. Participants (n = 5) were tested using the mini mental state examination (MMSE) and Alzheimer’s disease assessment scale (ADAS-cog; cognitive subscale) at baseline and 6 months. Both scales are valid measures of AD decline (Folstein et al., 1975; Kolibas et al., 2000). The BM intervention improved scores on both scales with 4/5 patients improving on the MMSE and 3/5 improving on the ADAS-cog (although there was a dissociation between the patient who improved on the two scales). These results are an indication that BM may have potential as an adjunct treatment for AD.

What’s in your bra?

This post is inspired by too many people and blogs to cite. Too too many to give adequate link-love.

From SHAPE Magazine to my fave Coco there have been an abundance of “whats in your gym bag?” or “whats in your purse?” posts.

And, seeing as Im the consummate misfit, each time I spy one I think:

I dont own a gym bag. I never carry a purse.  I stuff everything in my bra.

And, seeing as Im the consummate misfit, *thats* the post Ive longed to write.

When you see me like this:

971470 10151557121278432 216771226 n 300x225 Whats in your bra? Fitbloggin fashion show = hotel room key

Or this:

1000985 10152000671433765 146457484 n1 225x300 Whats in your bra? fashion show rehearsal = key & money

Or spy me sweaty:

6b80c7ea3be611e3847022000aaa0974 8 300x300 Whats in your bra? gum, keys, debit card.

Theres always a lot more there than meets the proverbial eye.

A lot more which I tend to either use right away (gum for coffee-breath, cash for food, key for key-stuff) or completely forget until I disrobe hours and hours later when I finally shower mere moments after exercising.

1017494 10152032604739466 224439547 n 300x300 300x300 Whats in your bra? mid-fashion show. mid ‘where is my key?!’ panic.

Today’s post was prompted by the cascade o’crap which launched forth yesterday when I de-bra’ed.

paper money.change.a pistachio I couldnt pry open.gum.a gum wrapper.a random red skull bead.20131006 055222 Whats in your bra? yep. bra-detritus.

As I watched the pistachio bounce across the floor I wondered, again, if Im the only woman who consistently has whole tree nuts fall when she disrobes.

And a post was born.

Merely so I can ask you:

Over-share with me.  Normalize for me. What’s in YOUR bra?

PSA: On the remotest chance there is any validity in the cell phone/breast cancer connection I urge you to never, ever tuck your phone in your bra.

25 Ways to get back on track

At one time or another had a serious fire and couldn't wait to start living healthier. The time will come when "novelty" disappears and you probably will lose a bit of motivation that began with. Let me first say that nobody is perfect and most of us has passed back on track several times. For some, returning to track it happens after a weekend full of eating garbage and for others it can mean to return to the track after a long hiatus. If it has been 2 days or 2 years, it is never late to return to the right path.

One of my rivals this month inspired me to write this post and in honor of our wedding anniversary today I present (July 25) a:

25 ways to get back on track

1. Follow-up of your intake of food today. No matter what you eat, you will learn from it.

2 Try a fast workout. Give a 5 minute walk, it is better than nothing!

3. Mix playlist. If your training with DVDs or in the gym, change the list of tracks to help you get pumped up again.

4. Drink water. Many people forget the drinks of the track when keeping a journal of food - beverages account also! If coffee, tea, alcohol, juice, etc...try one of these drinks replacing every day with a glass of ice cold water.

5 Take their workouts outside for a change of scenery.

6 Call someone cares about and tell them your short-term goal. This can help responsible.

7. Monitoring of your workouts. You can do this using a notebook or online using things like MyFitnessPal or TeamBeachbody (are all free!). Viewing to do these exercises will help to motivate you to keep going.

8. Try a new recipe. This always works for me! (AllRecipes.com and Pinterest.com are ideal for this)

9 Make a monthly challenge. There are tons of these available! It could be my challenge of 30 to 90 days or even something as simple as a challenge squatting or 30 days notice.

10. Reward yourself. If you are starting, reward yourself after a whole week with training without loss. (good ideas include a pinch of sports, training new songs or new gym shorts)

11 Start small. You don't have to touch the ground running. This could mean a small change in your diet (for example - pop drinking every 2 days instead of every day; this progress is)

12 Sign up in running. So far I've done several of them and I remember being afraid to death before my first race. Signature for your first 5 K will motivate you to continue working so that you are able to complete successfully running. And I promise that they are not so difficult and all other runners/walkers are very encouraging!

13 Start now. Do not wait until tomorrow or the dreaded Monday.

14. Plan your meals. I can not keep my diet very clean if not I plan my meals. Planning makes all the difference for me and it should not take long.

15 Recommit. Think * why you want to be healthy. WRITE DOWN IT.

16 Ignore sabotagers. I don't know if it's a Word, but it makes sense to me. You know that the people who I mean... which you shit because they noticed that these days are eating healthy. The polk fun because it avoids the doughnuts in the morning at work. Those making smartass comments about your lifestyle. Ugh! Let me tell you that people only do that is because it bothers them for their own good. It is not for you, it is for them.

17 Try a food challenge of 7 days. This can eat clean for 7 days or trying to a pale0 or a challenge gluten for 7 days. I made challenging paleo 30 days and that helped me out enormously although not hold 100% of the time now. Made me feel incredible!

18 Give you a new cookbook with healthy recipes! Some good are cookbooks of clean eating diet or the hungry girl.

19. Do not miss healthy lifestyle. Once you realize this, you can make things easier. When you know your "ideal weight" or "ideal body" you can not give. To reap the benefits of a healthy lifestyle, you have to commit for a lifetime! Not always mean things will be perfect... and you will have fights, but have the perseverance to not give up. ANY TIME. If going to do? He returned to this post to start again.:)

20 Ask your friends/family for help. Don't try to do it all on their own. Ask your spouse, partner, parents, cousins, aunts, uncles, etc., if they are committed with you. It is much easier if people living with (or spend much time with) are on board.

21 Reading books of personal development. This will help you to change your mentality and your mentality is so important when it comes to all aspects of your life. For example, right now I'm reading "Purpose driven life". They are small chapters so I can be a few minutes each day reading one. You might wonder how this will help you return to the right path, but try it for 7 days and I want to know how you feel. It is a change of life.

22. Turn the negative thoughts into positive. Easier said than do it, know it. But the effort is worthwhile and can make a difference! I've written about this several times on the blog here, here and here.

23. Forgive yourself.

24. Start a blog! It will help you hold yourself accountable and makes it easy to share your trip with others! That is why there is this blog and turned five this year.

25 Note that you deserve the body you desire - what this means for you! This blog is not about perfection...River front of perfection. Jajajajajaja. I have dents and gouges and do not understand always excited about workouts... but I know that I deserve what I have and in the end I'm working!

*****

Q. what it helps you stay on track? Below - share can only help someone also!